CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies

Central Nervous System Tumors

CD70, a novel target of CAR-T-cell therapy for gliomas

Neuro Oncol.

Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J

doi: 10.1093/neuonc/nox116.

Lymphoma

The CAR T Cell Story

healthbook TIMES Oncology Hematology

Russkamp N., Zenz T.

doi: 10.36000/hbT.OH.2019.01.001

COMMENTED

Lymphoma

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

★ 1 Recommended by Prof. Dr Stephan Bodis, Faculty Member

★ 2 Recommended and commented by Prof. Dr Christoph Renner, Faculty Member

doi: 10.1056/NEJMoa1914347.

Lung, Respiratory and Thoracic CancerLeukemiaLymphoma

Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies

J Thorac Oncol.

Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS

doi: 10.1016/j.jtho.2017.10.001.

LeukemiaLymphoma

CAR T-cell product performance in haematological malignancies before and after marketing authorisation

Lancet Oncol.

Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M

doi: 10.1016/S1470-2045(19)30729-6.

Lymphoma

Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma

Blood

Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL

doi: 10.1182/blood.2020007445

Leukemia

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

J Clin Oncol.

Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ

doi: 10.1200/JCO.19.03279.

Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

Expert Rev Hematol.

Namuduri M, Brentjens RJ

doi: 10.1080/

RECOMMENDED

Further Publications

T cell-engaging therapies - BiTEs and beyond

★ 1 Recommended by Prof. Dr Stephan Bodis, Faculty Member

doi: 10.1038/s41571-020-0347-5.

Related content

CD70, a novel target of CAR-T-cell therapy for gliomas

The CAR T Cell Story

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies

CAR T-cell product performance in haematological malignancies before and after marketing authorisation

Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

T cell-engaging therapies - BiTEs and beyond